PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease

Autor: Serdal Kanuncu, Francesco Fici, Nicolás Roberto Robles, Bahar Arican Tarim, Wim Makel, Elif Ilkay Yüce, Elif Ari Bakir
Rok vydání: 2019
Předmět:
0301 basic medicine
Male
Time Factors
endocrine system diseases
Angiotensin-Converting Enzyme Inhibitors
Blood Pressure
urologic and male genital diseases
Renin-Angiotensin System
chemistry.chemical_compound
0302 clinical medicine
Risk Factors
Prevalence
Diabetic Nephropathies
Lercanidipine
Middle Aged
Calcium Channel Blockers
female genital diseases and pregnancy complications
Europe
Treatment Outcome
Hypertension
Drug Therapy
Combination
Female
medicine.symptom
Cardiology and Cardiovascular Medicine
medicine.drug
medicine.medical_specialty
Urinary system
Urology
03 medical and health sciences
Angiotensin Receptor Antagonists
Diabetes mellitus
Internal Medicine
medicine
Diabetes Mellitus
Albuminuria
Humans
Renal Insufficiency
Chronic
Antihypertensive Agents
Aged
Creatinine
business.industry
medicine.disease
030104 developmental biology
Blood pressure
Cross-Sectional Studies
chemistry
Health Care Surveys
Microalbuminuria
business
030217 neurology & neurosurgery
Kidney disease
Zdroj: High blood pressurecardiovascular prevention : the official journal of the Italian Society of Hypertension. 27(1)
ISSN: 1179-1985
Popis: Albuminuria is an early marker of kidney disease and reduction of albuminuria translates into a decreased occurrence of cardiovascular and renal outcomes. To evaluate the changes in the prevalence of albuminuria in diabetic hypertensive patients treated with several combinations of renin-angiotensin aldosterone system with calcium channel blockers. We analysed data from 668 unselected patients from the PAIT survey (mean age 60.4 ± 10.2 years, prevalence of males 38%), with and without albuminuria, maintained for 6 months with the previous treatment with amlodipine-valsartan, amlodipine perindopril, lercanidipine-enalapril, verapamil-trandolapril, nitrendipine-enalapril and felodipine-ramipril Albuminuria was assessed, as urinary albumin–creatinine ratio, using a Multistic-Clinitek device analyzer. Microalbuminuria was defined as a loss of 3.4–33.9 mg albumin/mmol creatinine (30–300 mg/g) and macroalbuminuria as a loss of > 33.9 mg albumin/mmol creatinine (> 300 mg/g). Blood pressure was measured with a validated digital device. At baseline, albuminuria was present in 310 subjects (46.4%) (microalbuminuria in 263 (84.8%), macroalbuminuria in 15.2%), and normoalbuminuria in 53.6% 358. After 6 months, the prevalence of subjects with albuminuria was significantly lowered (p
Databáze: OpenAIRE
Externí odkaz: